OnKure Therapeutics
OKUR
66 hedge funds and large institutions have $41.3M invested in OnKure Therapeutics in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 21 reducing their positions, and 16 closing their positions.
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
8% more funds holding
Funds holding: 61 → 66 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.52% less ownership
Funds ownership: 82.15% → 81.63% (-0.52%)
9% less capital invested
Capital invested by funds: $45.4M → $41.3M (-$4.09M)
33% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$929K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$838K |
| 3 |
VPC
Vestal Point Capital
New York
|
+$423K |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$303K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$280K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.25M |
| 2 |
BlackRock
New York
|
-$1.19M |
| 3 |
State Street
Boston,
Massachusetts
|
-$298K |
| 4 |
Renaissance Technologies
New York
|
-$256K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$223K |
OKUR Hedge Fund Activity: Q2 2024 in Review
66 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2024, worth a combined $41.3M — down 9% from $45.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new OKUR positions and 16 closed out — a net gain of 5 holders — while 14 added to existing stakes and 21 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $929K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $1.25M sold.
- 66 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2024, up from 61 in Q1 2024.
- Funds reported $41.3M of OnKure Therapeutics stock for Q2 2024, down 9% quarter-over-quarter.
- 21 funds opened new OnKure Therapeutics positions in Q2 2024 and 16 closed out, a net change of +5 holders.
- The largest OnKure Therapeutics buyer in Q2 2024 was Nantahala Capital Management, an estimated $929K added.
- The largest OnKure Therapeutics seller in Q2 2024 was Rock Springs Capital Management, an estimated $1.25M sold.
Based on aggregated 13F filings for Q2 2024.